Senolytic cream accelerates wound repair in aged mice
A topical senolytic drug reduced senescent cells in aged mouse skin and sped up healing. The treatment reactivated inflammation, collagen, and blood vessel pathways. Further research is needed before human use.
The study, published in Aging (Aging-US), was conducted by researchers at Boston University's medical school. Senescent cells—damaged cells that stop dividing but remain in tissue—accumulate over time and release substances that disrupt normal repair processes. ABT-263 is an experimental senolytic agent designed to selectively eliminate these dysfunctional cells while preserving healthy ones.
Treatment was applied topically for five days before wounds were created. The brief inflammatory response appeared to prime the skin's repair mechanisms, and gene activity linked to collagen production and blood vessel formation increased. The researchers emphasize that the approach has only been tested in mice, and human safety and effectiveness remain unknown.
This research could eventually inform wound care for older adults, particularly those recovering from surgery or managing chronic conditions that slow healing. If senolytic treatments prove safe in human trials, they may reduce recovery times and complications from delayed wound closure. However, the findings are preliminary and limited to animal models; the temporary inflammatory response would require careful monitoring in humans. The approach may also raise broader questions about targeting cellular aging in other tissues.